{
    "id": 80372,
    "name": "epithelioid inflammatory myofibroblastic sarcoma",
    "source": "DOID",
    "definition": "An inflammatory myofibroblastic tumor composed of epithelioid or round cells with a characteristic perinuclear or nuclear membrane staining pattern with ALK immunohistochemistry, frequently dispersed in myxoid stroma with prominent neutrophils or lymphocytes, and often absence of plasma cells. [url:https\\://journals.sagepub.com/doi/full/10.1177/1066896918767557, url:https\\://www.ncbi.nlm.nih.gov/pubmed/21164297]",
    "currentPreferredTerm": null,
    "lastUpdateDateFromDO": "03/24/2020",
    "altIds": [
        
    ],
    "termId": "DOID:0080372",
    "evidence": [
        {
            "id": 3169,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK demonstrated sensitivity to Xalkori (crizotinib), which resulted in tumor shrinkage (PMID: 25028698).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 3659,
                    "pubMedId": 25028698,
                    "title": "A case report of epithelioid inflammatory myofibroblastic sarcoma with RANBP2-ALK fusion gene treated with the ALK inhibitor, crizotinib.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/25028698"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18604,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Xalkori (crizotinib) treatment resulted in significant clinical improvement and partial response lasted for 8 months in a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK (PMID: 30675302).",
            "molecularProfile": {
                "id": 11387,
                "profileName": "RANBP2 - ALK"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16333,
                    "pubMedId": 30675302,
                    "title": "ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18605,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, ALK G1269A was identified as an acquired mutation at disease progression in a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK treated with Xalkori (crizotinib) (PMID: 30675302).",
            "molecularProfile": {
                "id": 33477,
                "profileName": "RANBP2 - ALK ALK G1269A"
            },
            "therapy": {
                "id": 706,
                "therapyName": "Crizotinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 16333,
                    "pubMedId": 30675302,
                    "title": "ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 18606,
            "approvalStatus": "Case Reports/Case Series",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a clinical case study, Alunbrig (brigatinib) treatment resulted in rapid clinical improvement and reached a partial response 3 months after treatment in a patient with epithelioid inflammatory myofibroblastic sarcoma harboring RANBP2-ALK and an acquired ALK G1269A (PMID: 30675302).",
            "molecularProfile": {
                "id": 33477,
                "profileName": "RANBP2 - ALK ALK G1269A"
            },
            "therapy": {
                "id": 634,
                "therapyName": "Brigatinib",
                "synonyms": null
            },
            "indication": {
                "id": 80372,
                "name": "epithelioid inflammatory myofibroblastic sarcoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 16333,
                    "pubMedId": 30675302,
                    "title": "ALK-G1269A mutation in epithelioid inflammatory myofibroblastic sarcoma after progression on crizotinib: A case report.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30675302"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "clinicalTrials": [
        
    ]
}